TKI report

Categorized using metadata field perturbation

All reports

Gene signatures

Signatures (104) and Custom Report Builder
Title Organism Platform
1 Cirrhotic liver response to the antiangiongenic agent Sunitinib Rattus norvegicus Rattus norvegicus
2 Expression data from breast cancer tumors treated with a single window of the antiangiogenic agent Sunitinib Homo sapiens Homo sapiens
3 Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer Homo sapiens Homo sapiens
4 Gene expression profiles of Sunitinib-treated but not untreated short-term serum-free cultures predict treatment response of human high-grade gliomas in vitro Homo sapiens Homo sapiens
5 Effect of Sunitinib treatment withdrawal on Immunodeficient mice bearing MDA-MB231 tumors Mus musculus Mus musculus
6 Analysis of Gene Expression of Human Renal Cell Carcinoma by DNA Microaray in Patients treated with Sunitinib. An Exploratory Study Homo sapiens Homo sapiens
7 Differentiation of Mammary Tumors by SKI-606 (bostutinib) (gene expression) Mus musculus Mus musculus
8 Global gene expression changes in patient-derived CML cell line K562 after short- and long-term BCR-ABL kinase inhibition. Homo sapiens Homo sapiens
9 Global gene expression changes in patient-derived CML cell line K562 after short- and long-term BCR-ABL kinase inhibition. Homo sapiens Homo sapiens
10 Global gene expression changes in patient-derived CML cell line K562 after short- and long-term BCR-ABL kinase inhibition. Homo sapiens Homo sapiens
11 Fasting potentiates the anticancer activity of Crizotinib Homo sapiens Homo sapiens
12 Improved antitumor activity of immunotherapy combined with BRAF and MEK inhibitors in BRAFV600E mutant melanoma Mus musculus Mus musculus
13 Spectrum, clinical correlates and clinical implications of BRAF-inhibitor resistance mechanisms in melanoma Homo sapiens Homo sapiens
14 Anti-proliferative effects of continued mitogen activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma: Implications for treatment beyond disease progression Homo sapiens Homo sapiens
15 Anti-proliferative effects of continued mitogen activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma: Implications for treatment beyond disease progression Homo sapiens Homo sapiens
16 Spectrum, clinical correlates and clinical implications of BRAF-inhibitor resistance mechanisms in melanoma Homo sapiens Homo sapiens
17 Braf inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia, and exert anti-leukemic activity Homo sapiens Homo sapiens
18 Gene expression profiling of HDLM-2 Hodgkin lymphoma cell line after in vitro and in vivo treatment with Givinostat in combination with Sorafenib Homo sapiens Homo sapiens
19 Gene expression profiling of L-540 Hodgkin lymphoma cell line after in vitro and in vivo treatment with Givinostat in combination with Sorafenib Homo sapiens Homo sapiens
20 Gene expression profiling of HD-MyZ Hodgkin lymphoma cell line after in vitro and in vivo treatment with perifosine in combination with sorafenib Homo sapiens Homo sapiens
21 Gene expression analysis of Hodgkin lymphoma cell lines treated with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib Homo sapiens Homo sapiens
22 Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness associated with a D835 mutation Homo sapiens Homo sapiens
23 Expression in irradiated MEFs exposed to murine acute lymphoblastic leukemia cells Mus musculus Mus musculus
24 Imatinib and Nilotinib induced molecular changes in Philadelphia chromosome-positive Chronic Myelogenous Leukemia Homo sapiens Homo sapiens
25 Gene expression analysis in EGFR-mutant NSCLC cells treated with erlotinib versus DMSO Homo sapiens Homo sapiens
26 Gene expression analysis in EGFR-mutant NSCLC cells treated with erlotinib versus DMSO Homo sapiens Homo sapiens
27 Whole transcriptome analysis of erlotinib treatment in EGFR-mutant cells Homo sapiens Homo sapiens
28 Genome-wide analysis of EGFR inhibitor erlotinib treatment in Head and neck, squamous cell carcinoma's FADU, SQ20B and Cal 27 Homo sapiens Homo sapiens
29 Genome-wide analysis of EGFR inhibitor erlotinib treatment in Head and neck, squamous cell carcinoma's FADU, SQ20B and Cal 27 Homo sapiens Homo sapiens
30 Expression data from EGFR WT or EGFR mutant NSCLC with or without erlotinib Homo sapiens Homo sapiens
31 Genome-wide analysis of EGFR inhibitor erlotinib treatment in Head and neck, squamous cell carcinoma's FADU, SQ20B and Cal 27 Homo sapiens Homo sapiens
32 Microarray study to understand acquired resistance to EGFR-targeted therapy in lung cancer Homo sapiens Homo sapiens
33 Dynamic re-wiring of apoptotic signaling networks enhances tumor cell killing by DNA damage Homo sapiens Homo sapiens
34 Dynamic re-wiring of apoptotic signaling networks enhances tumor cell killing by DNA damage Homo sapiens Homo sapiens
35 Targeting FAK and EGFR/HER-2 with small molecule inhibitors in SKBR-3 breast cancer cell Homo sapiens Homo sapiens
36 Systems analysis of adaptive responses to MAP Kinase pathway blockade in BRAF mutant melanoma. Homo sapiens Homo sapiens
37 Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response Homo sapiens Homo sapiens
38 Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response Homo sapiens Homo sapiens
39 Lapatinib-resistant HER2-positive breast tumor cells Homo sapiens Homo sapiens
40 Lapatinib-resistant HER2-positive breast tumor cells Homo sapiens Homo sapiens
41 Bone marrow microenvironment effect on imatinib-treated chronic myeloid leukemia CD34+ cells Homo sapiens Homo sapiens
42 Chronic myelogenous leukemia response to imatinib: Philadelphia chromosome positive CD34+ cells Homo sapiens Homo sapiens
43 Chronic myelogenous leukemia CD34+CD38- cells response to histone deacetylase inhibitor analog and imatinib mesylate Homo sapiens Homo sapiens
44 Imatinib effects on chronic myelogenous leukemia CD34+ cells Homo sapiens Homo sapiens
45 Imatinib induces mesenchymal stem cell-mediated drug resistance in BCR-ABL–positive acute lymphoblastic leukemia Mus musculus Mus musculus
46 Imatinib induces mesenchymal stem cell-mediated drug resistance in BCR-ABL–positive acute lymphoblastic leukemia Mus musculus Mus musculus
47 Imatinib induces mesenchymal stem cell-mediated drug resistance in BCR-ABL–positive acute lymphoblastic leukemia Mus musculus Mus musculus
48 An EphB-Abl signaling pathway important for intestinal tumor initiation and growth Mus musculus Mus musculus
49 Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis Mus musculus Mus musculus
50 An EphB-Abl signaling pathway important for intestinal tumor initiation and growth Mus musculus Mus musculus
51 Effect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines Homo sapiens Homo sapiens
52 Effect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines Homo sapiens Homo sapiens
53 Effect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines Homo sapiens Homo sapiens
54 First ruxolitinib treatment of human alopecia areata patients Homo sapiens Homo sapiens
55 Effect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines Homo sapiens Homo sapiens
56 Effect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines Homo sapiens Homo sapiens
57 Effect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines Homo sapiens Homo sapiens
58 Effect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines Homo sapiens Homo sapiens
59 Effect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines Homo sapiens Homo sapiens
60 Effect of ruxolitinib treatment on gene expression in triple-negative breast cancer cell lines Homo sapiens Homo sapiens
61 Capturing drug responses by quantitative promoter activity profiling Homo sapiens Homo sapiens
62 EGFR Isoforms and Gene Regulation in Human Endometrial Cancer Cells Homo sapiens Homo sapiens
63 EGFR Isoforms and Gene Regulation in Human Endometrial Cancer Cells Homo sapiens Homo sapiens
64 EGFR Isoforms and Gene Regulation in Human Endometrial Cancer Cells Homo sapiens Homo sapiens
65 EGFR Isoforms and Gene Regulation in Human Endometrial Cancer Cells Homo sapiens Homo sapiens
66 Establishment of Afatinib-Resistant Non-Small Cell Lung Cancer Cells Derived from Tumor Xenograft Model [Afatinib treatment] Homo sapiens Homo sapiens
67 Establishment of Afatinib-Resistant Non-Small Cell Lung Cancer Cells Derived from Tumor Xenograft Model [Afatinib treatment] Homo sapiens Homo sapiens
68 Establishment of Afatinib-Resistant Non-Small Cell Lung Cancer Cells Derived from Tumor Xenograft Model [Afatinib treatment] Homo sapiens Homo sapiens
69 Prevention of Mouse AA with IL-15 pathway inhibitors Mus musculus Mus musculus
70 Prevention of Mouse AA with IL-15 pathway inhibitors Mus musculus Mus musculus
71 Treatment of established mouse AA with topical JAK inhibitors Mus musculus Mus musculus
72 Treatment of established mouse AA with topical JAK inhibitors Mus musculus Mus musculus
73 Treatment of established mouse AA with topical JAK inhibitors Mus musculus Mus musculus
74 Gene expression in Vemurafenib-treated A375 and A2058 melanoma cell lines Homo sapiens Homo sapiens
75 Gene expression in Vemurafenib-treated A375 and A2058 melanoma cell lines Homo sapiens Homo sapiens
76 Oncogenic BRAF harboring melanoma cell line response to BRAF inhibition Homo sapiens Homo sapiens
77 Braf inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia, and exert anti-leukemic activity Homo sapiens Homo sapiens
78 Braf inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia, and exert anti-leukemic activity Homo sapiens Homo sapiens
79 Parent vs. Induced drug tolerant cells Microarray Analysis Homo sapiens Homo sapiens
80 Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Homo sapiens Homo sapiens
81 Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Homo sapiens Homo sapiens
82 Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Homo sapiens Homo sapiens
83 Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Homo sapiens Homo sapiens
84 Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Homo sapiens Homo sapiens
85 Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Homo sapiens Homo sapiens
86 Cirrhotic liver response to the antiangiongenic agent Sunitinib Rattus norvegicus Rattus norvegicus
87 Expression data from renal cancer xenograft tumor treated with sunitinib or vehicle Homo sapiens Homo sapiens
88 Gene expression changes during resistance toward vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy in renal cell carcinoma (RCC) Homo sapiens Homo sapiens
89 Gene expression changes during resistance toward vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy in renal cell carcinoma (RCC) Homo sapiens Homo sapiens
90 GSE20921 Differentiation of Mammary Tumors by SKI-606 (bostutinib) (illumina) Mus musculus Mus musculus
91 Predominance of MAPK reactivation in early resistance to debrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma. Homo sapiens Homo sapiens
92 Gene expression profiling of HDLM-2 Hodgkin lymphoma cell line after in vitro and in vivo treatment with perifosine in combination with sorafenib Homo sapiens Homo sapiens
93 Gene expression profiling of L-540 Hodgkin lymphoma cell line after in vitro and in vivo treatment with perifosine in combination with sorafenib Homo sapiens Homo sapiens
94 GSE43053 - The multikinase inhibitor Sorafenib targets mitochondria and synergizes with glycolysis blockade for cancer cell killing. Rattus norvergicus Rattus norvergicus
95 Synthetic lethal screening with small molecule inhibitors provides a pathway to rational combination therapies for melanoma Homo sapiens Homo sapiens
96 Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response Homo sapiens Homo sapiens
97 Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response Homo sapiens Homo sapiens
98 Lapatinib-resistant HER2-positive breast tumor cells Homo sapiens Homo sapiens
99 Systems analysis of adaptive responses to MAP Kinase pathway blockade in BRAF mutant melanoma. Homo sapiens Homo sapiens
100 Systems analysis of adaptive responses to MAP Kinase pathway blockade in BRAF mutant melanoma. Homo sapiens Homo sapiens
101 Systems analysis of adaptive responses to MAP Kinase pathway blockade in BRAF mutant melanoma. Homo sapiens Homo sapiens
102 Systems analysis of adaptive responses to MAP Kinase pathway blockade in BRAF mutant melanoma. Homo sapiens Homo sapiens
103 Anastrozole/Fulvestrant/Gefitinib neoadjuvant therapy of estrogen receptor positive breast cancer patients: tumor core biopsies Homo sapiens Homo sapiens
104 Imatinib treatment of chronic myeloid leukemia cell lines: KU-812, KCL-22 and JURL-MK1 Homo sapiens Homo sapiens

PCA

Interactive 3D principal component analysis of gene signatures. You can rotate the visualization and mouse over the data points.

Genes

Hierarchical clustering of genes based on weights from the differential expression method.

Enrichr

Enrichr is a web tool that performs gene set enrichment analysis. To generate the hierarchical clusterings below, GEN3VA enriched each gene signature using Enrichr and then clustered the terms. Use the select button to change Enrichr's background library.

Hierarchical clustering of enriched terms from

L1000CDS2

L1000CDS2 is a web tool that queries the LINCS L1000 dataset to identify small molecules that can reverse or mimic the observed input expression pattern. To generate the hierarchical clustering below, GEN3VA enriched each gene signature using L1000CDS2 to generate a list of perturbations that either mimic (red) and reverse (blue) expression.